Payment overview · 2025
General Payments
$1,051.90
44 reported records · 18 companies
Healthcare provider profile · identity verified
Muhammad I Masroor, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · JEFFERSONVILLE, IN · NPI 1043216971
Verified facts
What the public records show
CMS Open Payments records show Muhammad I Masroor, M.D. received $1,051.90 in general payments during 2025 across 44 reported records.
AstraZeneca Pharmaceuticals LP accounted for 37.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Linzess, Lokelma, Rexulti, Trelegy Ellipta, Voquezna, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 135 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 266 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 266 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rexulti by this doctor in 2024.
Phathom Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VOQUEZNA as an associated drug or biological on 90302 records involving 33442 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Voquezna by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $389.51 | 37.0% | 10 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $95.98 | 9.1% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $74.69 | 7.1% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $59.19 | 5.6% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $57.64 | 5.5% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $55.60 | 5.3% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $43.14 | 4.1% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $42.40 | 4.0% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $38.06 | 3.6% | 2 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $32.92 | 3.1% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $30.20 | 2.9% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $22.21 | 2.1% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $20.76 | 2.0% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $20.47 | 1.9% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $18.83 | 1.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $17.64 | 1.7% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.37 | 1.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $15.29 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,051.90 | 44 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $204.18 | 6 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $150.50 | 3 | 2025 |
Source payment records
|
|||||
| LOKELMA Normalized: lokelma |
Drug | AstraZeneca Pharmaceuticals LP | $119.70 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $103.38 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $95.98 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $77.81 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $57.64 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $43.14 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $42.58 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $42.58 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $42.40 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $38.06 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $36.40 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $36.40 | 2 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $32.92 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $30.20 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $22.50 | 1 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $20.76 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $18.83 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $17.64 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $17.37 | 1 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $17.37 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $16.61 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $15.79 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $15.79 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.29 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 135 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 266 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 87 | exact normalized | Medicare Part D |
| LOKELMA lokelma |
2025 | Lokelma | 2024 | 38 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 44 | exact normalized | Medicare Part D |
| VOQUEZNA voquezna |
2025 | Voquezna | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
87 | 19 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
66 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
135 | 18 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
38 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
266 | 25 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
20 | 20 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
44 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
266 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
54 | 11 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Phathom Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | VOQUEZNA open payments reported associated product |
CMS Open Payments — General Payments 90302 supporting records · 33442 recipient NPIs · example record 1219216983 |
Voquezna · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 2968 | 343 |
| Eliquis | Apixaban | 1964 | 169 |
| Potassium Chloride | Potassium Chloride | 1484 | 199 |
| Omeprazole | Omeprazole | 1417 | 168 |
| Amlodipine Besylate | Amlodipine Besylate | 1344 | 167 |
| Furosemide | Furosemide | 1317 | 194 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1290 | 174 |
| Sertraline Hcl | Sertraline Hcl | 1163 | 126 |
| Pantoprazole Sodium | Pantoprazole Sodium | 1044 | 164 |
| Mirtazapine | Mirtazapine | 1040 | 115 |
| Tamsulosin Hcl | Tamsulosin Hcl | 949 | 113 |
| Carvedilol | Carvedilol | 889 | 97 |
| Divalproex Sodium | Divalproex Sodium | 887 | 85 |
| Trazodone Hcl | Trazodone Hcl | 856 | 107 |
| Gabapentin | Gabapentin | 825 | 142 |
| Metoprolol Succinate | Metoprolol Succinate | 822 | 131 |
| Metoprolol Tartrate | Metoprolol Tartrate | 797 | 112 |
| Metformin Hcl | Metformin Hcl | 738 | 85 |
| Clopidogrel | Clopidogrel Bisulfate | 725 | 94 |
| Donepezil Hcl | Donepezil Hcl | 641 | 65 |
| Lisinopril | Lisinopril | 641 | 100 |
| Losartan Potassium | Losartan Potassium | 604 | 75 |
| Escitalopram Oxalate | Escitalopram Oxalate | 553 | 71 |
| Levetiracetam | Levetiracetam | 551 | 60 |
| Buspirone Hcl | Buspirone Hcl | 543 | 75 |
| Hydralazine Hcl | Hydralazine Hcl | 442 | 74 |
| Ondansetron Hcl | Ondansetron Hcl | 440 | 102 |
| Bumetanide | Bumetanide | 400 | 53 |
| Duloxetine Hcl | Duloxetine Hcl | 383 | 50 |
| Famotidine | Famotidine | 374 | 49 |
| Citalopram Hbr | Citalopram Hydrobromide | 320 | 43 |
| Allopurinol | Allopurinol | 316 | 52 |
| Montelukast Sodium | Montelukast Sodium | 303 | 48 |
| Spironolactone | Spironolactone | 297 | 44 |
| Hydrochlorothiazide | Hydrochlorothiazide | 294 | 38 |
| Midodrine Hcl | Midodrine Hcl | 285 | 48 |
| Quetiapine Fumarate | Quetiapine Fumarate | 277 | 40 |
| Memantine Hcl | Memantine Hcl | 275 | 33 |
| Myrbetriq | Mirabegron | 273 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 272 | 24 |
| Jardiance | Empagliflozin | 266 | 25 |
| Xarelto | Rivaroxaban | 262 | 20 |
| Simvastatin | Simvastatin | 259 | 31 |
| Baclofen | Baclofen | 255 | 45 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 237 | 43 |
| Ropinirole Hcl | Ropinirole Hcl | 234 | 32 |
| Risperidone | Risperidone | 222 | 28 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 218 | 47 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 218 | 29 |
| Amiodarone Hcl | Amiodarone Hcl | 217 | 39 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 212 | 48 |
| Olanzapine | Olanzapine | 208 | 31 |
| Meloxicam | Meloxicam | 195 | 23 |
| Finasteride | Finasteride | 190 | 25 |
| Glipizide | Glipizide | 176 | 24 |
| Lamotrigine | Lamotrigine | 176 | 21 |
| Warfarin Sodium | Warfarin Sodium | 174 | 21 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 168 | 26 |
| Aripiprazole | Aripiprazole | 163 | 16 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 160 | 35 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 160 | 23 |
| Januvia | Sitagliptin Phosphate | 149 | 19 |
| Doxazosin Mesylate | Doxazosin Mesylate | 148 | 11 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 148 | 61 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 141 | 67 |
| Prednisone | Prednisone | 140 | 35 |
| Metformin Hcl Er | Metformin Hcl | 136 | 20 |
| Farxiga | Dapagliflozin Propanediol | 135 | 18 |
| Nystatin | Nystatin | 134 | 59 |
| Fluticasone Propionate | Fluticasone Propionate | 133 | 61 |
| Loperamide | Loperamide Hcl | 129 | 44 |
| Alendronate Sodium | Alendronate Sodium | 128 | 18 |
| Clonidine Hcl | Clonidine Hcl | 126 | 20 |
| Fenofibrate | Fenofibrate,micronized | 125 | 13 |
| Latanoprost | Latanoprost | 125 | 32 |
| Topiramate | Topiramate | 124 | 13 |
| Nifedipine Er | Nifedipine | 121 | 11 |
| Meclizine Hcl | Meclizine Hcl | 119 | 28 |
| Tizanidine Hcl | Tizanidine Hcl | 116 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 115 | 15 |
| Scopolamine | Scopolamine | 113 | 14 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 111 | 22 |
| Paroxetine Hcl | Paroxetine Hcl | 108 | 19 |
| Ezetimibe | Ezetimibe | 106 | 13 |
| Sucralfate | Sucralfate | 105 | 26 |
| Doxycycline Hyclate | Doxycycline Hyclate | 102 | 79 |
| Dicyclomine Hcl | Dicyclomine Hcl | 96 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 94 | 52 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 93 | 15 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 87 | 12 |
| Linzess | Linaclotide | 87 | 19 |
| Metoclopramide Hcl | Metoclopramide Hcl | 85 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 83 | 65 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 81 | 24 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 81 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 77 | 60 |
| Ranolazine Er | Ranolazine | 77 | suppressed |
| Ibuprofen | Ibuprofen | 76 | 21 |
| Propranolol Hcl | Propranolol Hcl | 76 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 76 | 29 |
| Benztropine Mesylate | Benztropine Mesylate | 72 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 72 | 49 |
| Fenofibrate | Fenofibrate Nanocrystallized | 70 | suppressed |
| Brilinta | Ticagrelor | 66 | suppressed |
| Bupropion Xl | Bupropion Hcl | 66 | 15 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 66 | 41 |
| Budesonide | Budesonide | 63 | 22 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 63 | 21 |
| Cephalexin | Cephalexin | 62 | 41 |
| Nebivolol Hcl | Nebivolol Hcl | 62 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 62 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 61 | 52 |
| Colestipol Hcl | Colestipol Hcl | 61 | 11 |
| Ondansetron Odt | Ondansetron | 61 | 24 |
| Promethazine Hcl | Promethazine Hcl | 61 | 11 |
| Humalog Kwikpen U-100 | Insulin Lispro | 60 | 20 |
| Chlorthalidone | Chlorthalidone | 58 | suppressed |
| Digoxin | Digoxin | 57 | 12 |
| Entresto | Sacubitril/Valsartan | 56 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 55 | 55 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 55 | 22 |
| Glipizide Er | Glipizide | 55 | 15 |
| Venlafaxine Hcl | Venlafaxine Hcl | 55 | suppressed |
| Atenolol | Atenolol | 54 | 14 |
| Atrovent Hfa | Ipratropium Bromide | 54 | 12 |
| Divalproex Sodium Er | Divalproex Sodium | 54 | 13 |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 54 | 15 |
| Lactulose | Lactulose | 54 | 14 |
| Trulicity | Dulaglutide | 54 | 11 |
| Diltiazem 24hr Er | Diltiazem Hcl | 53 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 53 | 32 |
| Diltiazem Hcl | Diltiazem Hcl | 51 | 11 |
| Gemtesa | Vibegron | 51 | suppressed |
| Premarin | Estrogens, Conjugated | 51 | suppressed |
| Haloperidol | Haloperidol | 48 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 48 | suppressed |
| Torsemide | Torsemide | 48 | 11 |
| Bupropion Hcl Sr | Bupropion Hcl | 47 | suppressed |
| Lansoprazole | Lansoprazole | 47 | suppressed |
| Metolazone | Metolazone | 47 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 46 | 18 |
| Glimepiride | Glimepiride | 45 | 11 |
| Novolog Flexpen | Insulin Aspart | 45 | 12 |
| Calcium Acetate | Calcium Acetate | 44 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 44 | suppressed |
| Lidocaine | Lidocaine | 44 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 44 | 16 |
| Cimetidine | Cimetidine | 43 | suppressed |
| Levofloxacin | Levofloxacin | 43 | 32 |
| Valsartan | Valsartan | 43 | suppressed |
| Amoxicillin | Amoxicillin | 42 | 15 |
| Fluconazole | Fluconazole | 42 | 27 |
| Lovastatin | Lovastatin | 42 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 42 | 13 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 41 | suppressed |
| Nitroglycerin | Nitroglycerin | 41 | 31 |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 40 | suppressed |
| Mupirocin | Mupirocin | 40 | 21 |
| Terazosin Hcl | Terazosin Hcl | 40 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 39 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 39 | 19 |
| Sulfasalazine | Sulfasalazine | 39 | suppressed |
| Gemfibrozil | Gemfibrozil | 38 | suppressed |
| Hydrocortisone | Hydrocortisone | 38 | 12 |
| Lidocaine Hcl | Lidocaine Hcl | 38 | 34 |
| Lokelma | Sodium Zirconium Cyclosilicate | 38 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 38 | 20 |
| Methocarbamol | Methocarbamol | 37 | 11 |
| Sotalol | Sotalol Hcl | 37 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 37 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 35 | 17 |
| Nyamyc | Nystatin | 35 | 21 |
| Galantamine Hbr | Galantamine Hbr | 34 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 34 | 11 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 34 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 33 | 11 |
| Azithromycin | Azithromycin | 33 | 31 |
| Breo Ellipta | Fluticasone/Vilanterol | 33 | 12 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 33 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 33 | 12 |
| Paliperidone Er | Paliperidone | 33 | suppressed |
| Anastrozole | Anastrozole | 32 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 32 | suppressed |
| Novofine Autocover | Pen Needle, Diabetic, Safety | 32 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 32 | suppressed |
| Admelog Solostar | Insulin Lispro | 31 | suppressed |
| Ketoconazole | Ketoconazole | 31 | 19 |
| Amantadine | Amantadine Hcl | 30 | suppressed |
| Clonidine | Clonidine | 30 | suppressed |
| Colchicine | Colchicine | 30 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 30 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 30 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 30 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 30 | 20 |
| Amitriptyline Hcl | Amitriptyline Hcl | 29 | 12 |
| Ceftriaxone | Ceftriaxone In Is-Osm Dextrose | 29 | 14 |
| Dantrolene Sodium | Dantrolene Sodium | 29 | suppressed |
| Meropenem-0.9% Nacl | Meropenem-0.9% Sodium Chloride | 29 | suppressed |
| Novolog | Insulin Aspart | 29 | suppressed |
| Nystop | Nystatin | 29 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 29 | 17 |
| Cefuroxime | Cefuroxime Axetil | 28 | 26 |
| Movantik | Naloxegol Oxalate | 28 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Humalog | Insulin Lispro | 27 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 27 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 25 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 25 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 24 | suppressed |
| Acetazolamide | Acetazolamide | 23 | suppressed |
| Cefdinir | Cefdinir | 23 | 17 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 23 | 11 |
| Metronidazole | Metronidazole | 23 | 14 |
| Oxybutynin Chloride | Oxybutynin Chloride | 23 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 22 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 22 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 22 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 22 | suppressed |
| Ozempic | Semaglutide | 22 | suppressed |
| Tradjenta | Linagliptin | 22 | suppressed |
| Vraylar | Cariprazine Hcl | 22 | suppressed |
| Primidone | Primidone | 21 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 21 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 21 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 20 | 20 |
| Celecoxib | Celecoxib | 20 | suppressed |
| Daptomycin | Daptomycin | 20 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 20 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 20 | suppressed |
| Folic Acid | Folic Acid | 20 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 20 | suppressed |
| Valganciclovir Hcl | Valganciclovir Hcl | 20 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 19 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 19 | suppressed |
| Ingrezza | Valbenazine Tosylate | 19 | suppressed |
| Mitigare | Colchicine | 19 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 18 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 18 | 13 |
| Rivastigmine | Rivastigmine | 18 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 18 | suppressed |
| Unifine Safecontrol Pen Needle | Pen Needle,dual Safety,diabetc | 18 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 17 | suppressed |
| Risperdal Consta | Risperidone Microspheres | 17 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 17 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 16 | suppressed |
| Lubiprostone | Lubiprostone | 16 | suppressed |
| Methylprednisolone | Methylprednisolone | 16 | 16 |
| Oxycodone Hcl | Oxycodone Hcl | 16 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 16 | suppressed |
| Roflumilast | Roflumilast | 16 | suppressed |
| Ursodiol | Ursodiol | 16 | suppressed |
| Clotrimazole | Clotrimazole | 15 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 15 | suppressed |
| Fluocinonide | Fluocinonide | 15 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 15 | suppressed |
| Klor-Con M20 | Potassium Chloride | 15 | suppressed |
| Levetiracetam Er | Levetiracetam | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 14 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 14 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 14 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 14 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 14 | suppressed |
| Phenytoin | Phenytoin | 14 | suppressed |
| Piperacillin-Tazobactam | Piperacillin Sodium/Tazobactam | 14 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 13 | suppressed |
| Vancomycin Hcl | Vancomycin/Water For Inj (Peg) | 13 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Arformoterol Tartrate | Arformoterol Tartrate | 12 | suppressed |
| Cefepime-Dextrose | Cefepime Hcl In Dextrose 5 % | 12 | suppressed |
| Clozapine | Clozapine | 12 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 12 | suppressed |
| Dexamethasone | Dexamethasone | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Rexulti | Brexpiprazole | 12 | suppressed |
| Riluzole | Riluzole | 12 | suppressed |
| Voquezna | Vonoprazan Fumarate | 12 | suppressed |
| Xifaxan | Rifaximin | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 11 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 11 | suppressed |
| Erythromycin | Erythromycin Base | 11 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 11 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Lamotrigine Er | Lamotrigine | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Rhopressa | Netarsudil Mesylate | 11 | suppressed |
| Tacrolimus | Tacrolimus | 11 | suppressed |
| Victoza 2-Pak | Liraglutide | 11 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,051.90 · 44 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, CAPLYTA, CREON, EVENITY, FANAPT, FARXIGA, HETLIOZ, JARDIANCE, Kerendia, LINZESS, LOKELMA, LYBALVI, OTEZLA, Omnipod, QULIPTA, REPATHA, REXULTI, TRELEGY ELLIPTA, UBRELVY, UZEDY, VOQUEZNA, VRAYLAR, Wegovy, YUPELRI, ZEPBOUND | 17 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error